What conclusions can we draw from these preliminary data for the use of BTK inhibitors to treat the hyperinflammatory immune response in patients with severe COVID-19?
How are you using telemedicine or other strategies to manage your patients with CLL during the COVID-19 pandemic?
Download this living slideset from the live Webinar on the management of patients with CLL during the COVID-19 pandemic and check back often for updates as the situation evolves and more data are available.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.